- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05416060
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age (Dulce Digital)
Study Overview
Status
Conditions
Detailed Description
Diabetes self-management education using digital platforms including, telehealth group visits, text-based messages and live delivery will result in improvements in diabetes health behaviors, patient engagement, health literacy and HbA1c.
Diabetes disproportionately affects racial and ethnic communities. The investigator developed Project Dulce, an American Diabetes Association-recognized and Medicare-approved Diabetes Self-Management Education and Support (DSME/S) program addresses the needs of a racially and ethnically diverse San Diego population and includes a multi-disciplinary team with peer educators delivering DSME/S. Previous trials have shown Project Dulce team-care improves clinical management and reduces costs and that the peer education alone improves clinical outcomes in Hispanics with Type 2 Diabetes across 10 months.
Mobile health (mHealth) technologies represent a viable way to overcome many of these barriers and extend the reach of DSME/S to participants who need it most.
During the coronavirus disease (COVID-19) pandemic, Project Dulce was adapted for group telehealth settings and delivered via the electronic medical record (EMR) scheduling system. Additionally, a previously developed text messaging platform-Dulce Digital was offered to extend the reach of the care team through educational and motivational messaging, medication reminders, and blood glucose monitoring prompts. A previous randomized controlled trial of Dulce Digital demonstrated a significant reduction of HbA1c across 10 months versus usual care in Hispanics with diabetes. While live Project Dulce and Dulce Digital programs have demonstrated improvements in clinical and cost outcomes in Hispanic patients, a comparative analysis of live, group telehealth and text messaging programs has not been done. This study will assess a direct comparison of each of these modalities to explore the feasibility, acceptance, and effectiveness of each delivery modality across Hispanic communities living with type 2 diabetes.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Athena Philis-Tsimikas, MD
- Phone Number: 858-678-7046
- Email: philis-Tsimikas.athena@scrippshealth.org
Study Contact Backup
- Name: Monica Ruiz, MA
- Phone Number: 858-678-7049
- Email: ruiz.monica@scrippshealth.org
Study Locations
-
-
California
-
Chula Vista, California, United States, 91910
- Recruiting
- Scripps Chula Vista Diabetes Center
-
Contact:
- Athena Philis-Tsimikas, MD
- Phone Number: 858-678-7046
-
Contact:
- Monica Ruiz, MA
- Phone Number: 858-678-7049
-
San Diego, California, United States, 92121
- Recruiting
- Scripps Whittier Diabetes Institute
-
Contact:
- Athena Philis-Tsimikas, MD
- Phone Number: 858-678-7046
-
Contact:
- Monica Ruiz, MA
- Phone Number: 858-678-7049
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hispanic/Latino adults who are registered patients of Scripps Health
- Diagnosis of Type 2 Diabetes
- HbA1c greater than or equal to 8% within the last 60 days
Exclusion Criteria:
- Severe illness precluding visits to clinic
- Liver function tests (ALT and AST) > 3 times the upper limit of normal
- Body mass index ≤ 23 kg/cm
- History of malignancy, except subjects who have been disease-free for >2 years, or whose only malignancy has been basal or squamous cell skin carcinoma
- Creatinine >3.5
- History of drug or alcohol abuse within 12 months prior to randomization
- Current enrollee in DSME/S
- Blood donation of one pint or more within the past 30 days, or plasma donation within 7 days prior to screening
- Anemia
- Lack of minimal literacy needed to participate in the text intervention
- Severe auditory or visual problems
- Primary language other than Spanish or English
- Not willing to carry a mobile phone
- Pregnant
- Plans to relocate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dulce Digital
Patients will participate in a text-based diabetes self-management educational and support (DSME/S) program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
|
Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum.
Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
|
Experimental: Project Dulce Telehealth DSME/S
Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
|
Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish.
The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors.
The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring.
It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
|
Experimental: Project Dulce Live DSME/S
Patients will participate in live a peer-led Telehealth diabetes self-management education and support program.
|
Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish.
The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors.
The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring.
It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 3 months
Time Frame: 3 months
|
Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 3 months; % Units HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast.
Samples will be process by Quest Diagnostics Inc and assayed by Immunoturbidimetry (integra 800, Roche).
Higher is worse.
|
3 months
|
Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months
Time Frame: 6 months
|
Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units HbA1c is measure of blood sugar level and assessed using blood samples following a 12-hour fast.
Samples will be process by Quest Diagnostics Inc and assayed by Immunoturbidimetry (integra 800, Roche).
Higher is worse.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Diabetes Distress (DDS-17) at 3 months
Time Frame: 3 months
|
The Diabetes Distress Scale (DDS-17) is a self-report instrument for adults with type 2 diabetes.
The scaled yields an overall distress score based on the average of response on the 1-6 scale for all 17 items.
The DDS-17 identifies three levels of specificity of diabetes distress information for use in clinical care, from overall emotional distress related to diabetes to highly specific sources of diabetes distress.
Higher score is worse.
|
3 months
|
Change from Baseline Diabetes Distress (DDS-17) at 6 months
Time Frame: 6 months
|
The Diabetes Distress Scale (DDS-17) is a self-report instrument for adults with type 2 diabetes.
The scaled yields an overall distress score based on the average of response on the 1-6 scale for all 17 items.
The DDS-17 identifies three levels of specificity of diabetes distress information for use in clinical care, from overall emotional distress related to diabetes to highly specific sources of diabetes distress.
|
6 months
|
Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 3 months
Time Frame: 3 months
|
The DTSQ scale has been shown to be useful in clinical trials evaluation of new technologies and has been used as one outcome indicator in routine audit diabetes care.
It is composed of 8 questions, scored by patients on a scale ranging from 0 ("very dissatisfied", "very inconvenient") to 6 ("very satisfied", "very convenient").
It is composed of 2 factors.
The first factor assesses treatment satisfaction (6 questions).
These questions ask about "satisfaction with current treatment", "flexibility", "convenience", "understanding of diabetes", "recommend treatment to others" and "willingness to continue", respectively.
The second factor (2 questions) which assess the burden from hyper- and hypoglycemia, respectively (0 "none of the time" to 6 "most of the time").
Treatment satisfaction is assessed as the sum of scores of 6 questions on the first factor (total score 36).
A higher score indicates higher treatment satisfaction.
|
3 months
|
Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 6 months
Time Frame: 6 months
|
The DTSQ scale has been shown to be useful in clinical trials evaluation of new technologies and has been used as one outcome indicator in routine audit diabetes care.
It is composed of 8 questions, scored by patients on a scale ranging from 0 ("very dissatisfied", "very inconvenient") to 6 ("very satisfied", "very convenient").
It is composed of 2 factors.
The first factor assesses treatment satisfaction (6 questions).
These questions ask about "satisfaction with current treatment", "flexibility", "convenience", "understanding of diabetes", "recommend treatment to others" and "willingness to continue", respectively.
The second factor (2 questions) which assess the burden from hyper- and hypoglycemia, respectively (0 "none of the time" to 6 "most of the time").
Treatment satisfaction is assessed as the sum of scores of 6 questions on the first factor (total score 36).
A higher score indicates higher treatment satisfaction.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Athena Philis-Tsimikas, MD, Scripps Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MISP-60691 (Other Grant/Funding Number: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Type 2
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
University of Campania "Luigi Vanvitelli"CompletedType 2 Diabetes MellitusItaly
-
Population Health Research InstituteNovo Nordisk A/SCompletedType 2 Diabetes MellitusCanada
-
Northwell HealthPatient-Centered Outcomes Research InstituteCompletedType 2 Diabetes Mellitus | Type 2 DiabetesUnited States
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusChina
-
University of MinnesotaUniversity of Southern California; Wake Forest UniversityCompleted
-
Joslin Diabetes CenterDHR Health Institute for Research and Development; Verizon FoundationCompletedType 2 Diabetes MellitusUnited States
Clinical Trials on Dulce Digital Text-Based Education
-
Scripps Whittier Diabetes InstituteNot yet recruiting
-
Scripps Whittier Diabetes InstituteSan Diego State University; University of California, San DiegoCompletedDiabetes Mellitus, Type 2United States
-
Scripps Whittier Diabetes InstituteNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Scripps Whittier Diabetes InstituteRecruiting
-
Scripps Whittier Diabetes InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); San... and other collaboratorsCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...Completed
-
Marmara UniversityNot yet recruitingClinical Reasoning | Self-efficacyTurkey
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
Trakya UniversityNot yet recruiting
-
University of California, San FranciscoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsRecruitingKidney Cancer | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Rectal Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Colon CancerUnited States